trial
as of 2026-07-01Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
NCTId NCT00615433
at a glance
Phase 3 · Completed
Enrollment 478 (actual)
Sponsored by Sumitomo Pharmaceuticals America
Primary completion 2009-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
478 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2008-01
Primary completion
2009-12
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Drugs
Indications
Sponsors
Sumitomo Pharmaceuticals AmericaLead Sponsor
Investigators
1
Medical Director, MDStudy Director
Sites
52 total
Little Rock, United StatesLittle Rock, United StatesCerritos, United StatesOceanside, United StatesOrange, United StatesParamount, United StatesSan Diego, United StatesSan Diego, United StatesTorrance, United StatesFruitland Park, United StatesNorth Miami, United StatesAtlanta, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
478
Phase
PHASE3
Primary Completion Date
2009-12
Status
COMPLETED
relationships
The graph out of here
drug
drug
drug
lead_sponsor
indication
indication
indication
investigator
person